Humalog's list price may have gone up, but Lilly says it got paid less per sale in 2018 versus 2014
As scrutiny into insulin pricing in the United States intensifies, Lilly is laying out the groundwork for its defense ahead of a third Congressional …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
